experimental animal modeling for immuno oncology

Experimental animal modeling for immuno-oncology

Affiliations.

• 1 Crown Bioscience Inc., 3375 Scott Blvd, Suite 108, Santa Clara, CA 95054, USA; State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China. Electronic address: [email protected].
• 2 HuMurine Technologies, Inc., 2700 Stockton Blvd, Rm. 1403, Sacramento, CA 95817, USA.
• 3 Crown Bioscience Inc., 3375 Scott Blvd, Suite 108, Santa Clara, CA 95054, USA.
• 4 Crown Bioscience Inc., 3375 Scott Blvd, Suite 108, Santa Clara, CA 95054, USA; State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China.
• PMID: 28167217
• DOI: 10.1016/j.pharmthera.2017.02.002

Immuno-oncology (I/O) research has intensified significantly in recent years due to the breakthrough development and the regulatory approval of several immune checkpoint inhibitors, leading to the rapid expansion of the new discovery of novel I/O therapies, new checkpoint inhibitors and beyond. However, many I/O questions remain unanswered, including why only certain subsets of patients respond to these treatments, who the responders would be, and how to expand patient response (the conversion of non-responders or maximizing response in partial responders). All of these require relevant I/O experimental systems, particularly relevant preclinical animal models. Compared to other oncology drug discovery, e.g. cytotoxic and targeted drugs, a lack of relevant animal models is a major obstacle in I/O drug discovery, and an urgent and unmet need. Despite the obvious importance, and the fact that much I/O research has been performed using many different animal models, there are few comprehensive and introductory reviews on this topic. This article attempts to review the efforts in development of a variety of such models, as well as their applications and limitations for readers new to the field, particularly those in the pharmaceutical industry.

Keywords: GEMM; Homograft; Humanization; Murine and human immunity; Syngeneic; Xenograft.

Copyright © 2017. Published by Elsevier Inc.

Publication types

• Disease Models, Animal*
• Drug Design
• Drug Discovery / methods
• Immunotherapy / methods*
• Molecular Targeted Therapy
• Neoplasms / drug therapy*
• Neoplasms / immunology
• Neoplasms / pathology

Advertisement

Animal Models for Cancer Immunology

• Published: 20 October 2023
• Volume 9 , pages 33–43, ( 2023 )

Cite this article

• Selen Kum Özşengezer   ORCID: orcid.org/0000-0002-7068-5979 1 &
• Zekiye S. Altun   ORCID: orcid.org/0000-0002-1558-4534 1  

209 Accesses

Explore all metrics

Purpose of Review

This review discusses the characteristics of different in vivo experimental immunologic models for the development of immunotherapies and the role of immunology in cancer.

Recent Findings

According to recent studies, different immunologic mouse models are being created using diverse strains and customized according to cancer type.

Cancer immunology and immunotherapy offer important therapeutic opportunities to develop new cancer treatments and improve patient survival. Unfortunately, immunotherapies do not always produce positive results. More studies, including patient-derived animal models, are needed to find new therapeutics and achieve positive immune responses against cancer. In particular, differentiated, humanized immunological mouse models, despite their limitations, facilitate the understanding of the mechanism of cancer therapeutics, the development of treatment modalities, drug administration, and the development of preclinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save.

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime

Price excludes VAT (USA) Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Rent this article via DeepDyve

Institutional subscriptions

Similar content being viewed by others

Humanized mouse models for the preclinical assessment of cancer immunotherapy.

Humanized mouse models for immuno-oncology research

Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice

Papers of particular interest, published recently, have been highlighted as: •  of importance •• of major importance.

Zou W, Wolchok JD, Chen L. PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4. https://doi.org/10.1126/scitranslmed.aad7118 .

Article   CAS   PubMed   PubMed Central   Google Scholar  

Zhao X, Subramanian S. Cancer immunology and immunotherapies: mechanisms that affect antitumor immune response and treatment resistance. Cancers. 2021;13:5655. https://doi.org/10.3390/cancers13225655 .

Article   PubMed   PubMed Central   Google Scholar  

Zhao X, Yuan C, Wangmo D, Subramanian S. Tumor-secreted extracellular vesicles regulate T-cell costimulation and can be manipulated to induce tumor-specific T-cell responses. Gastroenterology. 2021;161:560-574.e11. https://doi.org/10.1053/j.gastro.2021.04.036 .

Article   CAS   PubMed   Google Scholar  

Chulpanova DS, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Mouse tumor models for advanced cancer immunotherapy. Int J Mol Sci. 2020;21(11):4118. https://doi.org/10.3390/ijms21114118 .

Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013;1:12. https://doi.org/10.1186/2051-1426-1-12 .

Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250. https://doi.org/10.3389/fimmu.2019.02250 .

Najima Y, Tomizawa-Murasawa M, Saito Y, Watanabe T, Ono R, Ochi T, et al. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood. 2016;127:722–34. https://doi.org/10.1182/blood-2014-10-604777 .

Chulpanova DS, Kitaeva KV, Green AR, Rizvanov AA, Solovyeva VV. Molecular aspects and future perspectives of cytokine-based anti-cancer immunotherapy. Front Cell Dev Boil. 2020;8:402. https://doi.org/10.3389/fcell.2020.00402 .

Article   Google Scholar  

Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921–5. https://doi.org/10.1016/j.cub.2020.06.081 .

Baş Topcu KS. The role of the tumor microenvironment in tumor progression. Türk Nöroşir Derg. 2022;32(1):98–104.

Google Scholar  

Costa AC, Santos JMO, Gil da Costa RM, Medeiros R. Impact of immune cells on the hallmarks of cancer: a literature review. Crit Rev Oncol Hematol. 2021;168:103541. https://doi.org/10.1016/j.critrevonc.2021.103541 .

Article   PubMed   Google Scholar  

Schorey B. Tumour immunology: understanding the interplay between cancer and the immune system. J Clin Immunol. 2023;6(2):140. https://doi.org/10.35841/aacir-6.2.140 .

•• Chen A, Neuwirth I, Herndler-Brandstetter D. Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice. Cancers (Basel). 2023 May 30;15(11):2989. https://doi.org/10.3390/cancers15112989 . This paper has provided a clear description of the next generation of humanized mouse models and how they can be used to improve immuno-oncology clinical trial design.

Connolly KA, Fitzgerald B, Damo M, Joshi NS. Novel mouse models for cancer immunology. Annu Rev Cancer Biol. 2022;6(1):269–91. https://doi.org/10.1146/annurev-cancerbio-070620-105523 .

Stegelmeier AA, van Vloten JP, Mould RC, et al. Myeloid cells during viral infections and inflammation. Viruses. 2019;11(2):168. Published 2019 Feb 19. https://doi.org/10.3390/v11020168 .

Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–98. https://doi.org/10.1038/s41577-020-00490-y .

Li Z, Zheng W, Wang H, Cheng Y, Fang Y, Wu F, et al. Application of animal models in cancer research: recent progress and future prospects. Cancer Manag Res. 2021;15(13):2455–75. https://doi.org/10.2147/CMAR.S302565 .

Ireson CR, Alavijeh MS, Palmer AM, et al. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer. 2019;121:101–8. https://doi.org/10.1038/s41416-019-0495-5 .

Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013.

Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019;7:37.

Olson B, Li Y, Lin Y, Liu ET, Patnaik A. Mouse models for cancer immunotherapy research. Cancer Discov. 2018;8(11):1358–65. https://doi.org/10.1158/2159-8290.CD-18-0044 .

• Yin L, Wang XJ, Chen DX, Liu XN, Wang XJ. Humanized mouse model: a review on preclinical applications for cancer immunotherapy. Am J Cancer Res. 2020;10(12):4568–84 ISSN:2156–6976/ajcr0121335.  This paper focuses on the development of immunodeficient mice, as well as the structure and practicality of the humanized mouse model. It also discusses the benefits and downsides, as well as current breakthroughs in immunotherapy research for advanced usage in human cancer disorders.

Giannoni F, Hardee CL, Wherley J, Gschweng E, Senadheera S, Kaufman ML, et al. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther. 2013;21:1044–54. https://doi.org/10.1038/mt.2013.8 .

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci USA. 2011;108:E1408-1416. https://doi.org/10.1073/pnas.1115050108 .

Jacoby E, Shahani SA, Shah NN. Updates on CAR T-cell therapy in B-cell malignancies. Immunol Rev. 2019;290:39–59. https://doi.org/10.1111/imr.12774 .

Jin CH, Xia J, Rafiq S, Huang X, Hu Z, Zhou X, et al. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine. 2019;39:173–81. https://doi.org/10.1016/j.ebiom.2018.12.013 .

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–48. https://doi.org/10.1038/s41591-018-0036-4 .

Guil-Luna S, Sedlik C, Piaggio E. Humanized mouse models to evaluate cancer immunotherapeutics. Annu Rev Cancer Biol. 2021;5:119–36. https://doi.org/10.1146/annurev-cancerbio-050520-100526 .

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947–53. https://doi.org/10.1038/s41587-020-0462-y .

Li H, Song W, Li Z, Zhang M. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies. Front Immunol. 2022;11:992232. https://doi.org/10.3389/fimmu.2022.992232 .

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;11:197–218. https://doi.org/10.1038/s41573-018-0007-y .

Article   CAS   Google Scholar  

Flora, A. Evidence-based selection of the starting dose in first-in-human clinical trials using humanized mouse models. The Jackson Laboratory. Available online:  https://www.jax.org/news-and-insights/jax-blog/2022/april/evidence-based-selectionstarting-dose-in-human-clinical-trials . Accessed 21 Jul 2023.

•• Chen J, Liao S, Xiao Z, et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. Front Immunol. 2022;13:1007579. Published 2022 Oct 19. https://doi.org/10.3389/fimmu.2022.1007579 .  This work describe advances in humanized mouse models and immunodeficient mice, from the first nude mice lacking T lymphocytes to NOD/SCID rgnull mice lacking T, B, and NK cell populations.

Karnik I, Her Z, Neo SH, Liu WN, Chen Q. Emerging preclinical applications of humanized mouse models in the discovery and validation of novel immunotherapeutics and their mechanisms of action for improved cancer treatment. Pharmaceutics. 2023;15:1600. https://doi.org/10.3390/pharmaceutics15061600 .

Wege AK. Humanized mouse models for the preclinical assessment of cancer immunotherapy. BioDrugs. 2018;32(3):245–66. https://doi.org/10.1007/s40259-018-0275-4 .

• Allen TM, Brehm MA, Bridges S, et al. Humanized immune system mouse models: progress, challenges and opportunities. Nat Immunol. 2019;20(7):770–4. https://doi.org/10.1038/s41590-019-0416-z . This article describes the direct comparison of humanized mice generated with fetal tissue and mice generated with non-fetal tissue and the development of existing HIS mouse models to better recapitulate the human immune system.

Chen B, Liu H, Liu Z, Yang F. Benefits and limitations of humanized mouse models for human red blood cell related disease research. Front Hematol. 2023;1:1062705. https://doi.org/10.3389/frhem.2022.1062705 .

Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, et al. Humanized mice as a valuable pre-clinical model for cancer immunotherapy research. Front Oncol. 2021;11.

De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized mice for the study of immuno-oncology. Trends Immunol. 2018;39(9):748–63. https://doi.org/10.1016/j.it.2018.07.001 .

Moser J, van Ark J, van Dijk MC, Greiner DL, Shultz LD, van Goor H, et al. Distinct differences on neointima formation in immunodeficient and humanized mice after carotid or femoral arterial injury. Sci Rep. 2016;6:35387. https://doi.org/10.1038/srep35387 .

Brunetti JE, Kitsera M, Muñoz-Fontela C, Rodríguez E. Use of Hu-PBL mice to study pathogenesis of human-restricted viruses. Viruses. 2023;15(1):228. https://doi.org/10.3390/v15010228 .

Verma B, Wesa A. Establishment of humanized mice from peripheral blood mononuclear cells or cord blood CD34+ hematopoietic stem cells for immune-oncology studies evaluating new therapeutic agents. Curr Protoc Pharmacol. 2020;89:e77. https://doi.org/10.1002/cpph.77 .

Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat Commun. 2017;8:707. https://doi.org/10.1038/s41467-017-00786-z .

Saito Y, Shultz LD, Ishikawa F. Understanding normal and malignant human hematopoiesis using next-generation humanized mice. Trends Immunol. 2020;41(8):706–20. https://doi.org/10.1016/j.it.2020.06.004 .

Blinova E, Roshchin D, Kogan E, Samishina E, Demura T, Deryabina O, et al. Patient-derived non-muscular invasive bladder cancer xenografts of main molecular subtypes of the tumor for anti-Pd-L1 treatment assessment. Cells. 2019;8:526. https://doi.org/10.3390/cells8060526 .

Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023;20(3):192–206. https://doi.org/10.1038/s41571-022-00721-2 . Epub 2023 Jan 12 PMID: 36635480.

Jin KT, Du WL, Lan HR, Liu YY, Mao CS, Du JL, et al. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: a comprehensive review. Cancer Sci. 2021;112(7):2592–606. https://doi.org/10.1111/cas.14934 .

Tonomura N, Habiro K, Shimizu A, Sykes M, Yang Y-G. Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood. 2008;111:4293–6. https://doi.org/10.1182/blood-2007-11-121319 .

Pyo KH, Kim JH, Lee J-M, Kim SE, Cho JS, Lim SM, et al. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Lung Cancer Amst Neth. 2019;127:112–21. https://doi.org/10.1016/j.lungcan.2018.11.035 .

Lang J, Capasso A, Jordan KR, French JD, Kar A, Bagby SM, et al. Development of an adrenocortical cancer humanized mouse model to characterize anti-PD1 effects on tumor microenvironment. J Clin Endocrinol Metab. 2020;105:26–42. https://doi.org/10.1210/clinem/dgz014 .

Zschaler J, Schlorke D, Arnhold J. Differences in innate immune response between man and mouse. Crit Rev Immunol. 2014;31:433–54.

Chen Q, Wang J, Liu WN, Zhao Y. Cancer immunotherapies and humanized mouse drug testing platforms. Transl Oncol. 2019;11:987–95. https://doi.org/10.1016/j.tranon.2019.04.020 .

Download references

Author information

Authors and affiliations.

Department of Basic Oncology, Institute of Oncology, Dokuz Eylül University, İzmir, Turkey

Selen Kum Özşengezer & Zekiye S. Altun

You can also search for this author in PubMed   Google Scholar

Contributions

S.K.O and Z.A. wrote the main manuscript text and reviewed the manuscript.

Corresponding author

Correspondence to Selen Kum Özşengezer .

Ethics declarations

Conflict of interests.

The authors declare no conflict of interests.

Human and Animal Rights and Informed Consent

Because this is a brief overview, no human or animal research are included.

Additional information

Publisher's note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Özşengezer, S.K., Altun, Z.S. Animal Models for Cancer Immunology. Curr Mol Bio Rep 9 , 33–43 (2023). https://doi.org/10.1007/s40610-023-00154-5

Download citation

Accepted : 28 September 2023

Published : 20 October 2023

Issue Date : December 2023

DOI : https://doi.org/10.1007/s40610-023-00154-5

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Cancer immunology
• Animal models
• Humanized mouse models
• Find a journal
• Publish with us
• Track your research